Myhre syndrome is a developmental disorder characterized by reduced growth, generalized muscular hypertrophy, facial dysmorphism, deafness, cognitive deficits, joint stiffness, and skeletal anomalies. Here, by performing exome sequencing of a single affected individual and coupling the results to a hypothesis-driven filtering strategy, we establish that heterozygous mutations in SMAD4, which encodes for a transducer mediating transforming growth factor b and bone morphogenetic protein signaling branches, underlie this rare Mendelian trait. Two recurrent de novo SMAD4 mutations were identified in eight unrelated subjects. Both mutations were missense changes altering Ile500 within the evolutionary conserved MAD homology 2 domain, a well known mutational hot spot in malignancies. Structural analyses suggest that the substituted residues are likely to perturb the binding properties of the mutant protein to signaling partners. Although SMAD4 has been established as a tumor suppressor gene somatically mutated in pancreatic, gastrointestinal, and skin cancers, and germline loss-of-function lesions and deletions of this gene have been documented to cause disorders that predispose individuals to gastrointestinal cancer and vascular dysplasias, the present report identifies a previously unrecognized class of mutations in the gene with profound impact on development and growth.
Myhre syndrome (MIM 139210) is the eponym for the disorder originally described 30 years ago in two unrelated males exhibiting distinctive dysmorphic features, short stature, generalized muscular hypertrophy, cryptorchidism, limitation of joints, deafness, and intellectual disability. 1 Myhre syndrome is a rare condition with less than 30 affected individuals, mostly males, reported to date. [2] [3] [4] [5] [6] [7] [8] Based on the available records, cardinal features of Myhre syndrome include reduced growth, generalized muscular hypertrophy, variable cognitive deficits, a recognizable pattern of facial features (i.e., narrow palpebral fissures, midface hypoplasia, a small mouth with a thin upper lip, and prognathism), and skeletal anomalies (i.e., thick skull bones, platispondyly, large vertebral pedicles, broad ribs, hypoplastic iliac wings, and brachydactyly), joint stiffness, and deafness. Additional recurrent features include a cleft lip and/or palate, congenital heart defects, stiff skin, cryptorchidism, hypertension, and ocular defects. Myhre genetic relatedness among these disorders has been suggested. [9] [10] [11] Although the molecular basis for some of these clinically related conditions is unknown, increasing evidence supports the relevant role of transforming growth factor b (TGFb) signaling dysregulation in the pathogenesis of GPHYSD, ACMICD, and WMS. 12, 13 Here, an exome sequencing-based approach was used to identify similar to mothers against decapentaplegic (SMAD) family member 4 (SMAD4 [MIM 600993]), previously known as mothers against decapentaplegic homolog 4 (Drosophila) (MADH4), which encodes a protein with a crucial role in TGFb/bone morphogenetic protein (BMP) signal transduction, as the gene mutated in Myhre syndrome. Eight subjects with clinical features fitting Myhre syndrome were included in the study (Table 1 and Figure 1A ). Clinical data and biological material collection and storage were attained from the participating families in accordance with the ethical standards of the institutional review boards (Ospedale ''Bambino Gesù '', Rome; Università di Torino, Turin; Arcispedale Santa Maria Nuova, Reggio Emilia; Ospedale Microcitemico, Cagliari; Università ''Federico II'', Naples) and after written informed consent was secured. Genomic DNA was isolated from skin fibroblasts, hair bulb cells, peripheral blood leukocytes, saliva, and/or buccal mucosal epithelial cells with standard protocols. In all subjects, karyotype and Subjects   OBG_01  TO_01  TO_02  TO_03  RE_01  NA_01  NA_02  CA_01   Nucleotide substitution  1498A>G  1499T>C  1498A>G  1498A>G  1499T>C  1498A>G  1498A>G  1499T>C   Predicted amino acid  change   Ile500Val  Ile500Thr  Ile500Val  Ile500Val  Ile500Thr  Ile500Val  Ile500Val  Ile500Thr Paternal age at birth (years)   35  34  38  36  31  33  28  36 Length at birth (centile) n.a. 3rd <3rd 3rd <3rd n.a. n.a. <3rd
Weight at birth (centile) <3rd 3rd <3rd 3rd <3rd <3rd n.a. <3rd
Head circumference at birth (centile)
n.a. 3rd <3rd n.a. <3rd n.a. n.a. n.a.
Age at examination (years) 
Narrow mouth and/or thin upper lip
Cleft lip and/or palate
subtelomeric fluorescence in situ hybridization (FISH) analyses provided normal results. High-resolution arraycomparative genomic hybridization (CGH) or SNP array analyses were performed on three out of the eight subjects and did not disclose any disease-causing genomic rearrangement. Targeted enrichment and parallel sequencing experiments were performed on genomic DNA extracted from circulating leukocytes of a single affected subject (OBG_01). After fragment size selection, GS FLX Titanium adaptors (Roche) were ligated to the sheared genomic fragments to construct a shotgun sequencing library that was hybridized with a Sequence Capture Human Exome 2.1M Array v.2 (NimbleGen). Captured fragments were then amplified through emPCR and sequenced with Titanium reagents in a two-lane gasket PicoTiterPlate device (70X75) with a GS FLX instrument (Roche 454). Image analysis and base calling were performed with the GS FLX pipeline software (version 2.5.3). Approximately 1.2 Gb of genomic sequence from two GS FLX runs was obtained. The average read length was 380 bp, and fragment sizes ranged from 40 to 1,100 bp. Sequencing data were initially processed with the GSMapper software package v.2.5.3 (Roche), and high-quality sequencing reads were aligned to the human genome reference sequence (USCS hg19, GRCh37). Ninety-four percent of sequence reads mapped to the human reference genome. Targeted sequence coverage was 98%, and there was an average sequence depth of 103. Sequence alignment and functional annotation of the identified variants data were obtained with BEDTools v.2.12 14 predicted a potential deleterious effect on protein structure and/or function in 40% of those variants. Based on the evidence that all affected subjects were born to apparently healthy nonconsanguineous parents, we considered heterozygosity for a de novo mutation as the most likely event underlying the trait. This hypothesis was also supported by advanced paternal age in the majority of the reported cases as well as in subjects of the present cohort (Table 1) . In Myhre syndrome, the differential diagnosis usually considers GPHYSD. Based on the causative link of TGFb signaling to the latter, 12 Subjects   OBG_01  TO_01  TO_02  TO_03  RE_01  NA_01  NA_02  CA_01 Skin Anomalies
n.a. is used as an abbreviation for data not available. Subjects TO_3 and NA_01 were previously reported by Rulli et al. 5 and Titomanlio et al. Numbers below the domain structure indicate the amino acid boundaries of those domains. Nonsense (red circle) and truncating (pink triangle) mutations reported in juvenile polyposis syndrome (JPS) and JPS-hereditary hemorrhagic telangiectasia are shown below the illustration. The distribution of somatic SMAD4 mutations occurring in cancer (blue-filled peaks) is shown above the illustration. The location of Lys519, which is the residue subject to ubiquination, is also shown.
a somatic event ( Figure S1 , available online). Consistent with the notion that this SMAD4 de novo change was the causative mutation, the other confirmed candidate variants turned out to be inherited from one of the two healthy parents. These findings strongly pointed to SMAD4 as the gene mutated in Myhre syndrome.
To confirm the causal involvement of SMAD4 in Myhre syndrome, the entire coding sequence of the gene (NM_005359) was scanned for mutations in DNA obtained from circulating leukocytes from an additional seven unrelated affected subjects by direct sequencing with an ABI Prism 3500 Genetic Analyzers (Applied Biosystems) and the ABI BigDye Terminator Sequencing Kit v.3.1 (Applied Biosystems). Primer pairs designed to amplify exons and their intron boundaries are listed in Table S1 . Mutation analysis identified heterozygous SMAD4 mutations in all individuals. Among the seven subjects, four shared the c.1498A>G nucleotide change (p.Ile500Val), whereas the c.1499T>C change, predicting a different amino acid substitutions at the same codon (p.Ile500Thr), was identified in the three remaining individuals ( Figure S1 ). In all family trios, parental DNA genotyping demonstrated the de novo origin of each mutation, and STR genotyping confirmed paternity. Fibroblasts and/or epithelial cells were available for three of the seven subjects, and sequencing documented the defect, supporting the germline origin of these changes. Consistent with these findings, the c.1498A>G and c.1499T>C substitutions were not observed in more than 400 population-matched unaffected individuals scanned by high-resolution melting analysis and direct sequencing.
The Ile500 residue lies in the MAD homology 2 (MH2) domain, a region at the C terminus of the protein that is conserved among SMAD4 orthologs and paralogs ( Figures  S2 and S3 ) and known to represent the mutational hot spot for somatic and germline lesions occurring in malignancies and cancer-prone disorders ( Figure 1B) . 20 The MH2 domain mediates interaction with a wide variety of proteins, provides specificity and selectivity to SMAD function, and is indispensable for SMAD oligomerization, 21 which is required for TGFb/BMP signal transduction. Flow through this signaling network occurs through ligandinduced heteromeric receptor complexes consisting of type I and type II transmembrane serine/threonine receptors that recruit and phosphorylate receptor-regulated SMADs (R-SMADs), which in turn heterotrimerize with the common mediator, SMAD4. SMAD complexes then accumulate into the nucleus to regulate expression of target genes. 22 In the structure of the SMAD4 MH2 domain, Ile500 is located close to the protein surface, but it is solvent accessible only for 6% of the residue surface, because it is surrounded by and interacts with the hydrocarbon part of the side chains of residues Arg496, Arg497, Arg502, Glu526, and His528 ( Figure 2 ). With the exception of Arg496, these residues are highly conserved in SMAD4 orthologs and paralogs and constitute a binding site for anions. 23 The solvent-exposed location of this region and its highly charged character make it a likely candidate for protein-protein interactions and point to disturbed SMAD4 binding to signaling partners at this site as the possible effect promoted by the identified mutations. The best characterized complexes formed by SMAD4 are those resulting from its association with SMAD2 (MIM 601366) or SMAD3 (MIM 603109). Biochemical and crystallographic evidence indicates that these complexes are trimeric units comprising one SMAD4 and two (B) Ca ribbon trace (PDB ID codes 1U7F) of SMAD4 MH2 domain (cyan) and those of the two interacting SMAD3 subunits (orange and gray). Ile500 is represented in space-filling mode (red). Residues interacting with Ile500 (Arg496, Arg497, Arg502, Glu526, and His528) are shown as blue sticks. Asp493 (green), which is important for interdomain interactions, and Lys519 (violet), which is subject to ubiquination, are also shown. SMAD3 residues directly contributing to interactions with the evidenced SMAD4 residues (Ser275, Arg279, Glu284, and Arg287) are shown as yellow sticks, together with the phosphorylated SMAD3 serine residues (brown). The anion binding site located in proximity of Ile500, as indicated by the structure of the SMAD4 homotrimer (pdb code 1DD1), is shown by a yellow sphere. Visualization and analysis of the molecular structure was performed with the program UCSF Chimera. 46 phosphorylated R-SMAD subunits. The complex is characterized by three nonidentical interfaces, two of which involve separate solvent-exposed surfaces of the SMAD4 MH2 domain. 24 According to the crystal structure of the SMAD2/SMAD4 and SMAD3/SMAD4 heterotrimeric complexes, 24 Ile500 is located within one of the two MH2 surfaces involved in R-SMAD binding, and the residues surrounding it participate directly in the intermolecular interaction. Particularly, Arg497 and Asp493 form ion pairs with acidic residues of the R-SMAD subunit ( Figure 2B ). Although a number of missense mutations affecting conserved residues of this region (e.g., Asp493), which were documented or predicted to disrupt SMAD4 homo-and heteromerization, has been identified as somatic and/or germline lesions in malignancies and cancer-prone diseases (Catalogue of Somatic Mutations in Cancer, [COSMIC] and Human Gene Mutation Database [HGMD]) ( Figure 1B and Figure S2 ), no missense mutation affecting Ile500 has previously been reported in human disease.
To explore the consequences of the identified mutations on SMAD4 function, we performed structural analyses. We observed that residues Asp493 and Arg497, which are spatially close to Ile500 and are directly involved in intersubunit interactions in SMAD complexes, exhibit a significant conformational flexibility in the available SMAD4 crystallographic structures ( Figure S4 ). Interestingly, in the structures of R-SMADs, where a Thr residue is found at the position corresponding to Ile500, an orientation of the residue corresponding to Arg497 pointing away from the intersubunit interface is consistently observed ( Figure S4D ). Substitution of Ile500 by Thr or Val in SMAD4 is expected to weaken its hydrophobic interaction with apolar atoms of the surrounding charged residues by introducing a more hydrophilic and/or smaller side chain. This is hypothesized to perturb the arrangement of their side chains, which would affect proper function of the SMAD heterotrimer. Of note, several observations indicate that the region surrounding Ile500 is also critical for interactions with other signaling partners. For instance, the Arg496Ser and Arg502Ser substitutions have been shown to impair the transcriptional activity of the complex without affecting trimer formation. 25 Therefore, it is possible that the identified mutations might affect other functionally relevant protein-protein interactions of the mutant SMAD4. It is also of interest that, unlike R-SMADs, SMAD4 is not regulated by reversible phosphorylation. Instead, its function is controlled by monoubiquitination, 26 which occurs at Lys519 and has been proposed to sterically hamper the ability of the protein to form a stable complex with activated R-SMADs, resulting in pathway inhibition. 27 On the basis of these considerations, it can also be speculated that the subtle conformational change promoted by the Myhre syndrome-causing amino acid substitutions might impair proper SMAD4 ubiquitination and perturb signal flow by increasing the intracellular concentration of nonubiquitinylated SMAD4.
Detailed clinical information was obtained for all of the subjects heterozygous for a SMAD4 mutation (Table 1) . Overall, these subjects presented with a homogeneous phenotype ( Figure 1A ). Cardinal features of the syndrome, including short stature (< third centile), a recognizable facial appearance, generalized muscular hypertrophy, hearing loss, short hands, distinctive skeletal anomalies, and joint stiffness were observed in all individuals. All subjects presented with low birth weight but five became obese with age. Delayed psychomotor and/or language development and variable intellectual disability was documented in all but one individual. One subject exhibited noticeable psychological and behavioral issues. A wide spectrum of congenital heart defects and skin anomalies also recurred in the cohort, while macrocephaly, cleft lip and/or palate, refractive errors, and hypertension were less prevalent. Autistic behavior was documented in two subjects. Of note, none of the eight subjects exhibited any gross vascular anomaly or occurrence of skin, pancreatic, or gastrointestinal malignancies. Benign mesencephalic glioma and uncharacterized fibrous dysplasia of the maxilla, however, were reported in one individual ( Table 1) .
The TGFb signaling network controls a vast array of biological processes, including cell proliferation, differentiation, apoptosis, adhesion, and lineage commitment, in a cell type-dependent manner. [28] [29] [30] The TGFb superfamily of cytokines includes more than 30 structurally related proteins belonging to the two major TGFb/activin and BMP subfamilies. 31 Among them, TGFb family members play a diverse role in embryonic development, 32, 33 38, 39 The former is an autosomal-dominant disorder usually diagnosed within the first decade of life and characterized by hamartomatous polyps of the gastrointestinal tract and an increased risk of gastrointestinal cancer. 40 In the latter, the cancer-prone disease is associated with vascular dysplasia affecting multiple organs, consisting of telangiectases of the skin, oral and nasal mucosa, and arteriovenous malformations of the lungs, liver, brain, and gastrointestinal tract, which generally manifests by the fourth decade. 41 JPS/JP-HHT causative SMAD4 mutations are found throughout the gene and include nonsense, missense, and splice-site changes, as well as partial and complete gene deletions ( Figure 1B and Figure S2 ) (HGMD), 42 supporting a loss-of-function model of action. Consistent with this, loss of SMAD4 expression or function due to somatic inactivating intragenic lesions or gene deletions frequently occurs in carcinomas of the pancreas, gastrointestinal tract, and skin (COSMIC). In contrast, the invariant location and restricted spectrum of Myhre syndrome-causative mutations support the idea that these genetic lesions have distinct and specific consequences on SMAD4 function. Although the characterization of these mutants is required to appreciate the molecular mechanism(s) implicated in perturbation of growth and development driven by this previously unrecognized class of SMAD4 mutants, structural analysis suggests that they are likely to selectively interfere with the interaction of the protein to signaling partners, possibly by perturbing SMAD4 binding specificity and/or affinity. Heterozygous missense SMAD4 mutations were identified in all affected subjects with Myhre syndrome included in the study. This finding supports the idea that Myhre syndrome is a genetically homogeneous disorder, or, at minimum, that SMAD4 accounts for the preponderance of cases. The restricted spectrum of mutations seems to explain the relatively uniform phenotype characterizing this disorder. On the basis of the different clinical outcome of SMAD4 mutations, however, it cannot be excluded that additional, still unrecognized classes of gene variants might underlie clinically related conditions, including GOMBO syndrome, LAPS syndrome, Moore-Federman syndrome, and mutation-negative GPHYSD and ACMICD.
Recent advances in targeted sequence capture and massively parallel sequencing technologies offer new opportunities for our understanding of the molecular bases of Mendelian disorders, 43, 44 particularly those dramatically influencing the fitness of affected individuals. Candidate gene filtering strategies based on the use of ontologies of phenotypic features and cellular networks are predicted to enhance the power of such unbiased approaches even when coupled to the sequencing of single individuals with rare diseases. 4 Maria C. Digilio, 5 Maria L. Cavaliere, 6 Johanna M. van Hagen, 7 Giuseppe Zampino, 8 Ineke van der Burgt, 9 Giovanni B. Ferrero, 10 Laura Mazzanti, 11 Isabella Screpanti, 4 Helger G. Yntema, 9 Willy M. Nillesen, 9 Ravi Savarirayan, 12 Martin Zenker, 13 Bruno Dallapiccola, 5 Bruce D. Gelb, 14 and Marco Tartaglia 1, * RAS signaling plays a key role in controlling appropriate cell responses to extracellular stimuli and participates in early and late developmental processes. Although enhanced flow through this pathway has been established as a major contributor to oncogenesis, recent discoveries have revealed that aberrant RAS activation causes a group of clinically related developmental disorders characterized by facial dysmorphism, a wide spectrum of cardiac disease, reduced growth, variable cognitive deficits, ectodermal and musculoskeletal anomalies, and increased risk for certain malignancies. Here, we report that heterozygous germline mutations in CBL, a tumor-suppressor gene that is mutated in myeloid malignancies and encodes a multivalent adaptor protein with E3 ubiquitin ligase activity, can underlie a phenotype with clinical features fitting or partially overlapping Noonan syndrome (NS), the most common condition of this disease family. Independent CBL mutations were identified in two sporadic cases and two families from among 365 unrelated subjects who had NS or suggestive features and were negative for mutations in previously identified disease genes. Phenotypic heterogeneity and variable expressivity were documented. Mutations were missense changes altering evolutionarily conserved residues located in the RING finger domain or the linker connecting this domain to the N-terminal tyrosine kinase binding domain, a known mutational hot spot in myeloid malignancies. Mutations were shown to affect CBL-mediated receptor ubiquitylation and dysregulate signal flow through RAS. These findings document that germline mutations in CBL alter development to cause a clinically variable condition that resembles NS and that possibly predisposes to malignancies.
Supplemental Data
RAS signaling plays a crucial role in cell proliferation, migration, survival, and cell fate determination and differentiation and participates in early and late developmental processes, including organogenesis, morphology determination, and growth. 1 Because of its nodal role in signal transduction, signal traffic through RAS is tightly controlled, and enhanced flow through it contributes to oncogenesis. 2, 3 There are activating somatic RAS gene mutations in approximately 30% of human cancers, but the upregulation of this signaling pathway can also result from enhanced function of upstream signal transducers or RAS effectors, as well as from inefficient function of feedback mechanisms. However, the recent, unpredicted discovery of germline mutations in a number of genes encoding proteins involved in RAS signaling has established a novel scenario in which aberrant signal flow through RAS is causally linked to a group of clinically related developmental disorders, namely the neuro-cardio-facial-cutaneous syndromes (NCFCS), or RAS-opathies. CBL is a member of a small family of E3 ubiquitin ligases that negatively regulate intracellular signaling downstream of receptor tyrosine kinases (RTKs), but it also contributes to signal traffic through its adaptor function. 22 CBL is ubiquitously expressed and characterized by an N-terminal tyrosine kinase-binding (TKB) domain that is involved in protein-protein interaction and is connected by a short linker to a zinc-binding RING-finger domain mediating the E3 ubiquitin ligase activity ( Figure 1A ). The C-terminal portion of the protein includes an extensive proline-rich region containing a number of putative SH3-binding motifs, and this region is followed by multiple SH2-binding tyrosine phosphorylation sites and a ubiquitin-associated (UBA) domain overlapping with a leucine zipper (LZ) motif involved in ubiquitin binding and protein dimerization, respectively. 23 CBL mediates the conjugation of ubiquitin to activated RTKs; this conjugation is required for receptor internalization, endocytic sorting, and switching off signaling via receptor degradation or recycling. 24 Somatically acquired, mostly homozygous CBL mutations have recently been found to occur with variable prevalence in myeloproliferative disorders, including JMML, and myeloid leukemias. [25] [26] [27] [28] [29] [30] [31] [32] [33] They are largely small in-frame deletions or missense changes affecting the RING-finger domain and/or the adjacent linker region, and they appear to act in a dominant-negative fashion by uncoupling CBL binding to activated RTKs from their ubiquitylation and degradation. Given the link between the functions of CBL and RAS, 34 CBL's ubiquitous expression, and the negative modulatory role on signaling elicited by several RTKs-including the epidermal growth factor receptor (EGFR [MIM 131550])-that have roles in developmental processes, [35] [36] [37] as well as the contribution of impaired CBL function to leukemogenesis, particularly JMML, we hypothesized that this gene might be implicated in the pathogenesis of NS or related phenotypes. Three hundred and sixty-five subjects with NS or a phenotype suggestive of this disorder and without mutation in most of the previously identified disease genes (M.T., B.D., C.R., M.Z., and H.Y., unpublished data) were included in the study. The clinical features in most individuals satisfied the diagnostic criteria for NS, 8 but subjects lacking sufficient characteristics to allow a definitive diagnosis were also considered. DNA samples and clinical data were collected under research projects approved by an institutional review board, and informed consent for genetic analyses was obtained from all subjects included in the study. Genomic DNA was isolated from peripheral blood leukocytes, and the entire CBL coding sequence (NM_005188.2) was scanned for mutations. Primer pairs designed to amplify exons and their intron boundaries are listed in Table S1 . PCR amplifications were carried out with the high-fidelity Optimase Polymerase (Transgenomic) at conditions indicated by Optimase ProtocolWriter software (Transgenomic). Mutation analysis of the amplimers was performed via denaturing high-performance liquid chromatography (DHPLC) with the Wave 2100 System (Transgenomic) at column temperatures recommended by Navigator software, version 1.6.4.12 (Transgenomic). Amplimers with abnormal denaturing profiles were purified (Microcon PCR [Millipore] ) and then sequenced bidirectionally with the ABI BigDye Terminator Sequencing Kit v.1.1 (Applied Biosystems) and ABI Prism 3100 and 3730 Genetic Analyzers (Applied Biosystems). Mutation analysis allowed the identification of heterozygosity for a CBL mutation in four unrelated individuals (Figure 1B) . The c.1100A > C, c.1144A > G and c.1168G > T missense changes, predicting the Gln367Pro, Lys382Glu, and Asp390Tyr amino acid substitutions, respectively, were identified in three apparently sporadic cases. Parental DNA sequencing of the relevant exon demonstrated the de novo origin of the c.1100A > C and c.1168G > T transversions, and STR genotyping (AmpF/STR Identifier PCR Amplification Kit [Applied Biosystems]) confirmed paternity. In these cases, the defects were documented in hair bulb (c.1168G > T) and buccal epithelial (c.1100A > C and c.1168G > T) cell specimens, which excluded a somatic event restricted to hematopoietic cells ( Figure S1A available online). In case BO5149, the c.1144A > G change was documented as having been inherited from the father, who was originally deemed unaffected. Review of his clinical status, however, revealed minor signs and Chiari type 1 malformation (see below), the latter known to recur in NCFCS, which suggested markedly variable expressivity of the mutation. In the family transmitting the trait, the c.1259G > A transition, predicting the Arg420Gln substitution, cosegregated with disease. The inherited c.1144A > G and c.1259G > A changes were unobserved in more than 400 populationmatched unaffected individuals scanned by DHPLC analysis and direct sequencing, strongly arguing against the possibility that these variants were disease-unrelated polymorphisms occurring in the population. As expected, the two de novo CBL missense changes were not observed in the controls, further evidence that these variants were mutations. The four mutations affected residues evolutionarily conserved in CBL orthologs and paralogs ( Figure S1B ) that were located within the RING finger domain (Lys382, Asp390, and Arg420) or the adjacent linker connecting this domain to the N-terminal TKB domain (Gln367), a region that is known to represent the mutational hot spot for somatically acquired lesions occurring in malignancies. [25] [26] [27] [29] [30] [31] [32] 38, 39 According to the crystal structure of the TKB-linker-RING portion of CBL complexed with the ubiquitin-conjugating enzyme E2L 3 (UBE2L3 [MIM 603721]), 40 Lys382 and Arg420 are positioned on the RING surface involved in binding to UBE2L3 ( Figure 1C ). These residues are adjacent or close to four of the invariant cysteine residues that participate in the stabilization of the domain structure by binding the two tetrahedrally coordinated zinc ions. Lys382 is adjacent to residues involved in UBE2L3 binding, and Arg420 directly participates in this binding network. Missense mutations affecting Arg420, including the Arg420Gln substitution, or residues flanking Lys382 (Leu380, Cys381, Ile383, and Cys384) had previously been documented in chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) ( Figure S2) . 26, 27, [30] [31] [32] 38, 39 On the other hand, Asp390 is adjacent to a residue (Lys389) contributing to the intramolecular interaction involving the linker and RING domain with the TKB domain, which is critical for proper CBL function. 40, 41 Consistent with the hypothesis that the Asp390Tyr substitution affects the integrity of the RING-TKB interface, a missense change (Asp390Val) altering Asp390 has been reported in myeloid malignancies. 39 Similarly, Gln367 is located in a region of the linker that includes residues contributing to the intramolecular interaction with the TKB domain and UBE2L3 binding ( Figure 1C ). 40 The Gln367Pro substitution and a nonconservative amino acid change Gln367Lys affecting the same residue have been identified in CMML. 31 Detailed clinical information was obtained for the six identified subjects harboring CBL mutations ( Figure 1D ). The patient heterozygous for the c.1100A > C transversion (NMC-NS076) was referred because of developmental delay and congenital heart disease. His parents were nonconsanguineous, apparently healthy, and had no features suggestive for NS. Clinical examination at 9 years showed a triangular face with hypertelorism, mild palpebral ptosis, as well as large, slightly low-set ears. He had normal stature, a thorax with widely spaced nipples, and pectus excavatum. He had several café-au-lait spots, but no other ectodermal abnormalities were apparent. Cardiologic evaluation revealed an enlarged left atrium and transient chaotic ventricular dysrhythmias, an uncommon feature in NS. A head MRI scan showed delayed myelinization without structural abnormalities. Overall, his features were suggestive of NS but did not fulfill the clinical criteria for a definitive diagnosis.
The child heterozygous for the de novo c.1168G > T transversion (case ISS-S1N51) was initially referred at age 3 years. She displayed an unusual facial appearance (frontal bossing, wide nasal bridge, low-set and posteriorly rotated ears, and mild left-sided ptosis) and mild global developmental delay. She had generalized hypotonia in the newborn and infancy periods and severe feeding problems. Her early milestones were delayed; she achieved walking at age 21 months and had significant language delay. There was no organomegaly, and her cardiovascular system was normal. Clinical examination at 5 years showed still slightly delayed speech but improved motor skills. There was mild ectodermal involvement; she had fine and sparse scalp hair, widely spaced nipples, and a mild pectus excavatum anteriorly. Her height was at the tenth percentile. She had joint laxity at the elbows, shoulders, and fingers. At 15 years, dysmorphic features appeared less evident, and growth and IQ were in the normal range, but she continued to have low muscle tone generally and hyperextensible joints.
The subject inheriting the c.1144A > G substitution (case BO5149) was an 18-year-old girl who fulfilled the clinical criteria for the diagnosis of NS, exhibiting short stature (<3 rd percentile), distinctive facial features (hypertelorism, ptosis, downslanting palpebral fissures, epicanthal folds, and low-set, posteriorly rotated ears), a short neck with a marked pterigium colli, and a low posterior hairline. She presented with a bicuspid aortic valve with stenosis requiring surgical intervention. Other features included strabismus, thorax anomalies, cubitus valgus, hyperextensible joints, conductive hearing loss, and unilateral renal agenesis. Her 46-year-old father, who carried the missense change, did not show significant dysmorphic facial features, had a normal height, and showed no evidence of relevant cardiovascular and skeletal anomalies. He did have, however, a broad neck, low posterior hairline, and a Chiari type 1 malformation, a feature recurring in NS and clinically related disorders, [42] [43] [44] [45] that was complicated by tri-ventricular hydrocephalus and cervical syringomyelia resulting in weakness and hyperreflexia of the legs, sensory deficits of the trunk and lower right limb, and nystagmus, which required decompressive suboccipital craniectomy and cervical laminectomy. At six months of age, the girl (case HD316) inheriting the c.1259G > A transition from her affected father had a coarse, dysmorphic face (epicanthal folds, flat nasal bridge, thick lips, dysmorphic ears with thick helices, and a mid-face angioma). She had a short neck with redundant skin, thin hair, dysplastic toenails, dark skin, café-au-lait spots and streaks on the legs, and muscular hypotonia. Growth was in the normal range. Echocardiography revealed mild-to-moderate mitral valve insufficiency due to dysplastic leaflets. At 8 years of age, facial features and signs included pale-blue eyes, long philtrum, a thick and everted lower lip, and dysmorphic ears. Her hair was thin, dysplastic, and slow growing, and her eyebrows were sparse. Her neck was short, and her chest was broad with wide-spaced nipples. Her skin appeared dark and dry, and she had eczematous lesions on the face, keratosis pilaris, and café-au-lait streaks and spots on her legs. Her joints were hypermobile, and her voice was hoarse. Cognitive development was mildly delayed. A head MRI showed an abnormal corpus callosum with enlargement of the anterior portion and hypoplasia of the posterior region, as well as cerebellar vermis hypoplasia, the latter representing, to our knowledge, an unreported feature in NCFCS. Her 40-year-old father showed a high forehead, sparse eyebrows, down-slanting palpebral fissures, thick lips, thick helices, a short neck, a broad chest, pectus excavatum, and dry and dark skin with hyperpigmented lesions in the sacral region. Bilateral cryptorchidism was operated upon at 8 years of age. Developmental milestones were achieved normally, but learning difficulties were recorded. None of the six subjects heterozygous for a CBL mutation exhibited any hematologic anomaly or malignancy.
To explore the consequences of the identified mutations on CBL ubiquitin ligase activity as well as their effects on RAS signal output, we transiently expressed HA-tagged Asp390Tyr and Arg420Gln CBL mutants in COS-1 cells and evaluated the levels of EGFR ubiquitylation and the extent of signal flow through the MAPK and PI3K-AKT cascades (Figure 2 ). These mutations were selected as representatives of the two classes of lesions affecting residues located at the interface between the TKB and RING-finger domains (Gln367Pro and Asp390Tyr) or facing toward the E2 ubiquitin-conjugating enzyme (Lys382Glu and Arg420Gln). Compared to that of the wild-type CBL protein, expression of each mutant resulted in impaired receptor ubiquitylation in response to EGF stimulation. These findings are in line with previous studies focused on leukemia-associated CBL mutations, indicating that these lesions impair CBL ubiquitin ligase function, weaken CBL-mediated degradation of cell-surface receptors, and have a dominant-negative effect on the wild-type protein. 26 , and SHOC2). Here, we report that germline missense mutations affecting the linker region or the RING finger domain of CBL, a known negative regulator of activated RTKs, can underlie a condition resembling NS or conditions with clinical features partially overlapping it, and we thereby identify a previously unpredicted consequence of dysregulated CBL function in human disease. One mechanism by which intracellular signaling is switched off is RTK downregulation through receptor internalization and degradation. CBL contributes to this process as an adaptor molecule with ubiquitin ligase activity. 23 It has been shown that direct or GRB2-mediated binding of CBL to EGFR is required for multiple monoubiquitylation of the activated receptor. Ubiquitylation of EGFR is followed by its internalization in clathrincoated vesicles that fuse with internal vesicles to form endosomes, from where ubiquitylated EGFR is sorted to lysosomes for degradation while nonubiquitylated EGFR is recycled back to the plasma membrane. In this process, CBL function is required in the sorting step for efficient EGFR downregulation. 46, 47 On the basis of these considerations, mutations impairing the ubiquitin ligase activity of CBL are expected to promote enhanced intracellular signal flow through inefficient receptor degradation, which is consistent with the present findings and recently published data. 26, 31 Hinting at the present findings, acquired CBL mutations affecting the RING-finger domain and the adjacent linker stretch had been shown to contribute to the pathogenesis of myeloid leukemias and myeloproliferative disorders, including JMML. In JMML, CBL mutations are largely missense; residue Tyr371 is mutated in the majority of cases. 27, 29 These lesions are mutually exclusive from PTPN11, KRAS, NRAS, and NF1 mutations, which also occur in this myeloproliferative disorder. This finding supports the functional equivalence of CBL defects in causing enhanced RAS signaling, at least in precursor cells of the myeloid lineage. 27, 29 Although the location and type of identified mutations are compatible with the idea that this newly identified condition results from the dominant-negative effect of one mutated CBL allele, it should be considered that CBL is also believed to regulate signaling positively, for example as part of the MAPK and PI3K/AKT pathways, via its adaptor function. [48] [49] [50] This positive modulatory role is attained through binding to a plethora of proteins and functioning as a scaffold allowing the formation of multiprotein complexes mediating signal flow. Although we cannot formally exclude effects on this still poorly characterized positive modulatory function, the fact that the disease-causing mutations are far from the known binding sites makes this unlikely. In JMML and other myeloid malignancies, CBL mutations generally occur as homozygous lesions as a result of acquired isodisomy, which suggests that the contribution of a CBL mutant to leukemogenesis requires either loss of function of the wild-type protein or increased dosage of the mutated allele. 27, 31, 32 Although no hematological malignancy was documented in the six subjects carrying a germline CBL mutation, this consideration supports the idea that the identified heterozygous condition for a germline CBL mutation might represent a condition that predisposes to malignancies. A similar scenario within the NCFCS family is observed in neurofibromatosis type I (NF1 [MIM 162200]), in which a second, somatic loss-offunction mutation or deletion of the wild-type NF1 allele is associated with the development of malignancies.
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NF1 is a relatively common autosomal-dominant disorder characterized by café-au-lait spots, neurofibromas, Lisch nodules, axillary and inguinal freckling, and recurrent features comprising reduced growth, skeletal defects, deficits in cognitive function, and increased risk for certain malignancies, including JMML. Similar to findings of the present study, a markedly wide phenotypic spectrum is associated with germline mutations in the NF1 gene; even within the same family, some patients are mildly affected, and others have severe manifestations of disease. Neurofibromin, the NF1 gene product, is a negative modulator of RAS function, which partly explains the overlap with NS in some patients and the resulting socalled neurofibromatosis-Noonan syndrome (NFNS [MIM 601321]). 52, 53 Although analysis of wider cohorts will be required to characterize more precisely the phenotypic spectrum associated with germline CBL mutations, the present findings indicate that these lesions are associated with a strikingly variable phenotype and that clinical features might be quite subtle. Several lines of evidence, however, support the idea that the heterozygous condition for a germline CBL mutation underlies a previously unrecognized disorder resembling or partially overlapping NS. First, no missense change affecting the linker region and the adjacent RING-finger domain was identified in more than 400 unaffected population-matched subjects. Such a nonrandom distribution of sequence variants is statistically significant (Fisher's exact probability < 0.05). Second, two mutations arose de novo in the germline. Third, the mutations altered highly conserved residues in CBL orthologs and paralogs located in protein domains functionally required for CBL-mediated signaling to be properly switched off. Moreover, they overlapped in position and, in some cases, with the precise substitution of somatic CBL mutations observed in human cancers. Fourth, the four germline CBL missense mutations have functional effects on signal transduction. Previous and present characterization of three of the mutants identified in this study showed impairment of CBL ubiquitin ligase activity and derangement of signaling through ERK and AKT.
Overall, the present data indicate that CBL gene mutations underlie a clinically variable condition that can resemble NS phenotypically. CBL mutations are likely to account for a small portion of subjects with features fitting NS (<1%), but they might be more common among subjects with clinical features partially overlapping NS or a phenotype that is suggestive of this disorder, and particularly among subjects with NS/JMML without mutations in the PTPN11, NF1, or RAS genes. These findings provide evidence that CBL functional dysregulation can significantly perturb a wider range of cellular processes than was previously known and have a direct impact on development. Molecular genetic as well as structural and functional data support the view that disease-associated CBL mutations perturb intracellular signaling by affecting receptor metabolism (i.e., recycling versus degradation) rather than directly altering signal flow at the level of RAS or its downstream effectors, which represents the first evidence for disorders of the NCFCS family. Additional work will need to provide a more precise delineation of the phenotypic spectrum associated with germline mutations in CBL as well as their molecular diversity and functional consequences in intracellular signaling and development.
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